SOPH
VENTE TOTALE: 61 000 titres (~452 671,48 $ US)
- Insiders
- HIBBS KATHY L, Camblong Jurgi
- Total bought
- —
- Total sold
- $452,671
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-11
Despite a meaningful earnings catalyst with 27% revenue growth and a raised outlook, SOPH's severely distressed financial foundation — marked by persistent losses, negative free cash flow, and deteriorating equity —…
The first sentence of the analysis written for SOPH on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.9% | 67.4% | 68.8% | 65.7% | 62.4% | |
| Ebit Margin | -95.7% | -91.1% | -124.9% | -182.8% | -180.1% | |
| Ebitda Margin | -83.3% | -77.9% | -111.5% | -171.1% | -171.2% | |
| Operating Profit Margin | -91.8% | -102.1% | -120.0% | -184.7% | -176.7% | |
| Pretax Profit Margin | -101.6% | -94.0% | -125.9% | -184.2% | -181.7% | |
| Continuous Operations Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Net Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Bottom Line Profit Margin | -102.2% | -95.9% | -126.6% | -183.9% | -182.1% | |
| Current Ratio | 1.961 | 3.709 | 4.156 | 7.320 | 9.889 | |
| Quick Ratio | 1.835 | 3.490 | 3.974 | 7.128 | 9.689 | |
| Solvency Ratio | -0.597 | -0.916 | -1.291 | -1.873 | -1.565 | |
| Cash Ratio | 1.391 | 2.993 | 3.460 | 6.017 | 6.746 | |
| Price To Earnings Ratio | -3.991 | -3.232 | -3.861 | -1.515 | -10.602 | |
| Price To Earnings Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Forward Price To Earnings Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Price To Earnings Diluted Ratio | -3.991 | -3.232 | -3.861 | -1.515 | -10.602 | |
| Price To Earnings Diluted Growth Ratio | -0.172 | 0.146 | 0.375 | -0.672 | -0.170 | |
| Price To Book Ratio | 6.690 | 2.093 | 2.014 | 0.660 | 2.831 | |
| Price To Sales Ratio | 4.082 | 3.099 | 4.890 | 2.776 | 19.276 | |
| Price To Free Cash Flow Ratio | -8.174 | -3.960 | -5.276 | -1.641 | -12.068 | |
| Price To Operating Cash Flow Ratio | -8.298 | -4.716 | -6.278 | -1.884 | -13.458 | |
| Debt To Assets Ratio | 0.386 | 0.193 | 0.090 | 0.069 | 0.041 | |
| Debt To Equity Ratio | 1.337 | 0.311 | 0.123 | 0.084 | 0.047 | |
| Debt To Capital Ratio | 0.572 | 0.237 | 0.109 | 0.077 | 0.045 | |
| Long Term Debt To Capital Ratio | 0.503 | 0.121 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.467 | 1.610 | 1.361 | 1.218 | 1.163 | |
| Working Capital Turnover Ratio | 1.276 | 0.704 | 0.443 | 0.225 | 0.236 | |
| Operating Cash Flow Ratio | -0.752 | -1.598 | -1.364 | -2.614 | -2.026 | |
| Operating Cash Flow Sales Ratio | -0.492 | -0.657 | -0.779 | -1.474 | -1.432 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | 1.191 | 1.190 | 1.148 | 1.115 | |
| Debt Service Coverage Ratio | -14.255 | -27.174 | -119.145 | -127.135 | -105.483 | |
| Interest Coverage Ratio | -15.574 | -34.798 | -127.255 | -137.438 | -108.646 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.603 | -1.426 | -2.611 | -4.186 | -4.437 | |
| Capital Expenditure Coverage Ratio | -66.221 | -5.238 | -5.265 | -6.752 | -8.685 | |
| Dividend Paid And Capex Coverage Ratio | -66.221 | -5.238 | -5.265 | -6.752 | -8.685 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.785 | -2.990 | -2.879 | 0.154 | -8.663 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.9% | ▼-5.5% | ▼-3.4% |
| Ebit Margin | -95.7% | ▼-4.6% | ▲39.2% |
| Ebitda Margin | -83.4% | ▼-5.5% | ▲39.7% |
| Operating Profit Margin | -91.8% | ▲10.3% | ▲43.3% |
| Pretax Profit Margin | -101.6% | ▼-7.6% | ▲35.9% |
| Continuous Operations Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Net Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Bottom Line Profit Margin | -102.2% | ▼-6.3% | ▲35.9% |
| Current Ratio | 1.961 | ▼-1.748 | ▼-3.446 |
| Quick Ratio | 1.835 | ▼-1.655 | ▼-3.388 |
| Solvency Ratio | -0.597 | ▲0.319 | ▲0.651 |
| Cash Ratio | 1.391 | ▼-1.602 | ▼-2.730 |
| Price To Earnings Ratio | -3.991 | ▼-0.760 | ▲0.648 |
| Price To Earnings Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Forward Price To Earnings Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Price To Earnings Diluted Ratio | -3.991 | ▼-0.760 | ▲0.648 |
| Price To Earnings Diluted Growth Ratio | -0.172 | ▼-0.318 | ▼-0.074 |
| Price To Book Ratio | 6.690 | ▲4.597 | ▲3.833 |
| Price To Sales Ratio | 4.082 | ▲0.983 | ▼-2.743 |
| Price To Free Cash Flow Ratio | -8.174 | ▼-4.215 | ▼-1.950 |
| Price To Operating Cash Flow Ratio | -8.298 | ▼-3.582 | ▼-1.371 |
| Debt To Assets Ratio | 0.386 | ▲0.192 | ▲0.230 |
| Debt To Equity Ratio | 1.337 | ▲1.026 | ▲0.956 |
| Debt To Capital Ratio | 0.572 | ▲0.335 | ▲0.364 |
| Long Term Debt To Capital Ratio | 0.503 | ▲0.383 | ▲0.378 |
| Financial Leverage Ratio | 3.467 | ▲1.857 | ▲1.703 |
| Working Capital Turnover Ratio | 1.276 | ▲0.571 | ▲0.699 |
| Operating Cash Flow Ratio | -0.752 | ▲0.845 | ▲0.918 |
| Operating Cash Flow Sales Ratio | -0.492 | ▲0.165 | ▲0.475 |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | ▼-0.176 | ▼-0.117 |
| Debt Service Coverage Ratio | -14.255 | ▲12.919 | ▲64.383 |
| Interest Coverage Ratio | -15.574 | ▲19.224 | ▲69.168 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.603 | ▲0.823 | ▲2.050 |
| Capital Expenditure Coverage Ratio | -66.221 | ▼-60.984 | ▼-47.789 |
| Dividend Paid And Capex Coverage Ratio | -66.221 | ▼-60.984 | ▼-47.789 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.785 | ▼-1.795 | ▼-0.952 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $315.4M | $202.0M | $305.0M | $132.0M | $779.7M | |
| Enterprise value | $308.1M | $151.8M | $200.3M | -$12.5M | $599.8M | |
| EV / Sales | 3.99x | 2.33x | 3.21x | -0.26x | 14.83x | |
| EV / Op. cash flow | -8.11x | -3.54x | -4.12x | 0.18x | -10.35x | |
| EV / Free cash flow | -7.99x | -2.98x | -3.47x | 0.16x | -9.28x | |
| EV / EBITDA | -4.79x | -2.99x | -2.88x | 0.15x | -8.66x | |
| Net debt / EBITDA | 0.11x | 0.99x | 1.50x | 1.78x | 2.60x | |
| Current ratio | 1.96x | 3.71x | 4.16x | 7.32x | 9.89x | |
| Income quality | 0.48x | 0.70x | 0.62x | 0.80x | 0.79x | |
| Graham net-net | -$0 | $0 | $1 | $2 | $4 | |
| Tax burden | 100.7% | 102.0% | 100.6% | 99.8% | 100.2% | |
| Interest burden | 106.2% | 103.2% | 100.8% | 100.7% | 100.9% | |
| Working capital | $48.6M | $72.6M | $112.4M | $169.4M | $254.3M | |
| Invested capital | $102.5M | $121.0M | $162.7M | $210.8M | $285.9M | |
| Return on assets | -48.3% | -40.2% | -38.3% | -35.9% | -23.0% | |
| Operating ROA | -44.5% | -36.8% | -33.3% | -31.1% | -31.6% | |
| Return on tangible assets | -61.9% | -49.5% | -44.1% | -39.1% | -24.2% | |
| Return on equity | -167.6% | -64.8% | -52.2% | -43.7% | -26.8% | |
| Return on invested capital | -61.3% | -50.9% | -43.1% | -39.9% | -24.4% | |
| Return on capital employed | -62.8% | -51.8% | -43.9% | -40.5% | -24.5% | |
| Earnings yield | -25.0% | -30.9% | -25.9% | -66.2% | -9.4% | |
| Free cash flow yield | -12.2% | -25.3% | -19.0% | -60.9% | -8.3% | |
| Capex / Op. cash flow | -1.5% | -19.1% | -19.0% | -14.8% | -11.5% | |
| Capex / Depreciation | 6.0% | 95.1% | 110.7% | 186.3% | 184.8% | |
| Capex / Sales | 0.7% | 12.5% | 14.8% | 21.8% | 16.5% | |
| SG&A / Sales | 110.2% | 117.1% | 131.0% | 176.8% | 173.6% | |
| R&D / Sales | 43.4% | 52.7% | 59.3% | 74.4% | 65.7% | |
| Stock comp / Sales | 0.0% | 25.3% | 24.4% | 28.6% | 21.0% | |
| Intangibles / Total assets | 22.0% | 18.7% | 13.2% | 8.2% | 4.9% | |
| Days sales outstanding | 88d | 49d | 89d | 62d | 64d | |
| Days payables outstanding | 66d | 33d | 42d | 49d | 56d | |
| Operating cycle | 166d | 150d | 211d | 177d | 201d | |
| Cash conversion cycle | 100d | 116d | 168d | 129d | 145d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+56.2%EV / Sales ▲+71.3%EV / EBITDA ▼-60.0%EV / Op. cash flow ▼-4.563Earnings yield ▲+0.059
Profitability
Return on equity ▼-1.028Return on assets ▼-0.081Return on invested capital ▼-0.104Return on capital employed ▼-0.110Operating ROA ▼-0.077Income quality ▼-0.218Tax burden ▼-0.013
Efficiency
Days sales outstanding ▲+38.847Days payables outstanding ▲+32.651Operating cycle ▲+16.684Cash conversion cycle ▼-15.968Capex / Sales ▼-0.118R&D / Sales ▼-0.093
Balance-sheet strength
Current ratio ▼-1.748Net debt / EBITDA ▼-0.876Working capital ▼-24051000.000Invested capital ▼-18488000.000Intangibles / Total assets ▲+0.033
Change over 5 years
Valuation
Market cap ▼-59.5%EV / Sales ▼-73.1%EV / EBITDA ▲+44.8%EV / Op. cash flow ▲+2.246Earnings yield ▼-0.156
Profitability
Return on equity ▼-1.408Return on assets ▼-0.253Return on invested capital ▼-0.370Return on capital employed ▼-0.383Operating ROA ▼-0.129Income quality ▼-0.307Tax burden ▲+0.004
Efficiency
Days sales outstanding ▲+23.547Days payables outstanding ▲+9.846Operating cycle ▼-35.067Cash conversion cycle ▼-44.913Capex / Sales ▼-0.157R&D / Sales ▼-0.223
Balance-sheet strength
Current ratio ▼-7.928Net debt / EBITDA ▼-2.485Working capital ▼-205701000.000Invested capital ▼-183391000.000Intangibles / Total assets ▲+0.171
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-27 When Unusual Volume Isn''t Noise: 3 Small-Caps Sending Signals The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That''s because volume can provide an important measure of the conviction behind a stock''s price movement.
- 2026-08-25 SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next? SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares trading hands. The stock had previously closed at $8.65. Analyst Ratings Changes SOPH has been the subject of a
- 2026-08-04 SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
- 2026-08-04 SOPHiA GENETICS Q2 Earnings Call Highlights SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.
- 2026-08-04 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue was $23.3 million, up 27% year-over-year Gross margin was 64.6% on a reported basis and 72.1% on an adjusted basis, compared to 67.0% reported and 74.4% adjusted in the prior year period Net loss was $22.4 million, flat year-over-year; Adjusted EBITDA loss was $8.8 million, improving 27% year-over-year The company is raising 2026 revenue guidance to a range of $94 million to $96 million, representing 22% to 24% year-over-year growth.
- 2026-08-04 SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS''s decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.
- 2026-07-21 SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
- 2026-06-22 SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026 ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the agenda, electing Dr. Jurgi Camblong as the Executive Chairman of the Board of Directors with 99.79% of the votes, and Ross Muken as a member of the Board of Directors for the first time with 99.88% of the votes. Mr. Muken will assume the role of Chief Executive Officer, effective July 1, 2026.
- 2026-06-19 SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters'' Option to Purchase Additional Shares BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares at the public offering price, less the underwriting discounts and commissions.
- 2026-06-18 SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH''s platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint.